Fischer Medical Ventures Ltd

At Rs 40.69, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Fischer Medical Ventures Ltd locked at its upper circuit of 3.92% on 30 Mar 2026, with buyers queuing and no sellers willing to part with shares.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, has seen its investment rating upgraded from Sell to Hold as of 27 March 2026. This change reflects a nuanced improvement across technical indicators, financial trends, valuation metrics, and overall company quality, despite some lingering concerns over management efficiency and market performance.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, has witnessed a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. The stock’s recent price momentum, coupled with evolving technical indicators such as MACD, RSI, and moving averages, suggests a cautious but watchful stance for investors as the company transitions from a previously bearish outlook to a mildly bearish technical trend.

Fischer Medical Ventures Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

At Rs 37.09, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Fischer Medical Ventures Ltd locked at its upper circuit of 4.44% on 25 Mar 2026, with buyers queuing and no sellers willing to part with shares.

Fischer Medical Ventures Ltd’s share price declined to a fresh 52-week low of ₹32.09 on 24 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a series of challenges impacting investor sentiment and valuation metrics.

At Rs 33.65, sellers were still queuing — but there were no buyers willing to take the other side. Fischer Medical Ventures Ltd locked at its lower circuit of 5% on 23 Mar 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a thinly traded stock.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, surged to hit its upper circuit limit on 18 Mar 2026, closing at ₹36.60 with a robust gain of 4.99% on the day. This sharp rally was driven by intense buying pressure, a significant rise in delivery volumes, and a notable gap-up opening, signalling renewed investor interest despite the company’s recent downgrade to a Sell rating by MarketsMOJO.

Fischer Medical Ventures Ltd surged to its upper circuit limit on 17 Mar 2026, closing at ₹34.86, marking a maximum daily gain of 5.0%. The stock demonstrated robust buying interest, outperforming its sector and reversing a three-day losing streak despite trading below key moving averages. However, regulatory restrictions have frozen further trading, leaving significant unfilled demand in the market.

Fischer Medical Ventures Ltd has seen its investment rating downgraded from Hold to Sell as of 16 March 2026, driven primarily by deteriorating technical indicators, expensive valuation metrics, and subdued financial trends despite recent strong quarterly results. The company’s Mojo Score now stands at 47.0, reflecting a cautious stance amid ongoing market challenges and weak price momentum.

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, has touched a new 52-week low of Rs.32.92 as of 16 Mar 2026, marking a significant decline amid broader market pressures and company-specific performance factors.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a bearish trend. Despite a modest upgrade in its Mojo Grade from Sell to Hold, the stock’s price action and technical parameters suggest caution for investors amid ongoing volatility.

Fischer Medical Ventures Ltd has seen its investment rating upgraded from Sell to Hold as of 11 March 2026, reflecting a nuanced assessment of its financial performance, valuation metrics, and market participation. Despite strong quarterly results and a debt-free balance sheet, concerns over management efficiency and valuation remain, prompting a cautious stance from analysts.

Fischer Medical Ventures Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, witnessed intense selling pressure on 5 Mar 2026, hitting its lower circuit limit and closing at ₹35.12. The stock declined by 3.79% on the day, underperforming both its sector and the broader market, as panic selling and unfilled supply weighed heavily on investor sentiment.